Alexa Elias

Alexa Elias

Auto-generated profile, based on publicly available information

Alexa Elias

SHARE Collaborative, Blizard Institute Queen Mary University of London London UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2024 in Cambridge Prisms: Global Mental Health
Verified
Journal Article
Open access
PDF file
AEAlexa Elias
Alexa Elias
NSNadine Seward
Nadine Seward
CLCrick Lund
Crick Lund
Psychological interventions have demonstrated effectiveness in treating perinatal depression (PND), but understanding for whom, how and under what conditions they improve symptoms in low- and middle-income countries (LMICs) is largely unknown. This review aims to synthesise current knowledge about predictors, moderators and mediators of psychological therapies to treat PND in LMICs. Five databases were searched for studies quantitatively examining the effects of at least one mediator, moderator or predictor of therapies for PND in LMICs. The review sampled seven publications evaluating findings from randomised trials conducted in Asia and sub-Saharan Africa. The small number of included studies limited generalisability of findings. Analyses of trials with acceptable quality suggest that patient activation in Pakistan and social support in both India and Pakistan may mediate psychotherapy effectiveness, higher baseline depression severity may moderate treatment response in South Africa, and shorter depression duration at baseline may moderate intervention response in India. This review highlights current gaps in evidence quality and the need for future trials exploring PND psychotherapy effectiveness in LMICs to follow reporting guidelines to facilitate appropriate predictor, moderator and mediator analyses.

27 September 2022 in Frontiers in Psychology
Verified
Journal Article
Open access
AEAlexa Elias
Alexa Elias
ABAdam D. Brown
Adam D. Brown
Patterns of memory sharing begin early in one’s life, informing relationships, one’s history, and one’s sense of cultural belonging. Memory sharing among families has been the focus of research investigating the relationship between mental health and intergenerational memory. A burgeoning body of research is showing that intergenerational knowledge of one’s family history is associated with positive mental health and wellbeing. However, research on the specific mechanisms and potential applications of such findings are just beginning to emerge. In particular, studies examining intergenerational storytelling point to the importance of culture and gender as critical factors underlying how stories are told and the extent to which these stories are associated with wellbeing. Such findings hold important promise for the pentation and treatment of mental health issues. As research in this area continues to evolve, the identification and characterization of factors and mechanisms underlying intergenerational family stories and wellbeing may help to guide the integration of family stories into mental health interventions.

13 June 2025 in HIV Medicine
Verified
Journal Article
Open access
KRKyle Ring
Kyle Ring
AEAlexa Elias
Alexa Elias
Megan DevonaldMegan Devonald
Megan Devonald
MSMelanie Smuk
Melanie Smuk
COChloe Orkin
Chloe Orkin
Introduction: Randomized controlled trial evidence suggests that long‐acting injectable (LA‐I) cabotegravir and rilpivirine (CAB+RPV) has similar virological failure (VF) rates to daily oral therapy, but clinical practice evidence is lacking. Integrase inhibitor (INI) resistance may limit future therapy. The optimal regimen is uncertain. Methods: We synthesized evidence from PubMed, EMBASE, Cochrane and conference abstract databases through 18 November 2024, to identify observational cohort studies (OCS) that reported on VF events in virally suppressed individuals who switched to LA‐I CAB+RPV. We extracted data on VF, resistance‐associated mutations (RAMs) at VF, post‐VF regimen choice and re‐suppression. We assessed the risk of bias using a modified Downs and Black tool. Results: VF definitions differed considerably among OCS, with 172 individuals experiencing VF across 79 cohorts that included 13 899 individuals. Twenty‐eight cohorts ( n = 7987) reported genotypic information at VF. Out of the 80 VF events with genotypic information available at the time of the VF event, NNRTI mutations were identified in 45 cases, INIs in 40 cases, and dual‐class resistance in 33 cases. Notably, 28 VF events were not accompanied by resistance. Post‐VF regimen choices were reported for 92 VF events. Regimens used were protease inhibitor (PI)‐based, oral INI‐based and some physicians continued LA‐I CAB+RPV post‐VF. Re‐suppression occurred in 87.8% (65/74) of VF events in which it was described. Conclusions: In OCS, VF was a very uncommon occurrence and comparable with clinical trials. However, when it did occur, it was frequently accompanied by resistance. Post‐VF regimens used to achieve suppression varied, including LA‐I CAB+RPV maintenance and were highly successful.

13 September 2025 in HIV Medicine
Verified
Journal Article
Open access
AEAlexa Elias
Alexa Elias
CPChloé Pasin
Chloé Pasin
MSMelanie Smuk
Melanie Smuk
APAmy Paterson
Amy Paterson
COChloe M. Orkin
Chloe M. Orkin
Background: When using long‐acting injectable cabotegravir and rilpivirine (CAB + RPV) in individuals with viraemia, beyond small cohorts, little is known about baseline characteristics, virological failure outcomes, resistance emergence, re‐suppression and discontinuation. Methods: We identified evidence from PubMed , EMBASE , Cochrane and conference abstract databases through 17 March 2025 to synthesize data from observational cohort studies ( OCS ) that reported on virological failure ( VF ) events in individuals with viraemia at initiation of LA ‐I CAB + RPV . We extracted data on baseline clinical and socio‐demographic characteristics, VF , resistance‐associated mutations ( RAMs ) at VF , post‐ VF regimen choice, re‐suppression and discontinuation. Results: Across 14 cohorts including 561 individuals, there were 36 VF events ( OCS ‐level VF rate 0% ( n / N = 0/12, 0/12 and 0/10) to 25% ( n / N = 3/12)). VF definitions varied. 6/14 OCS ( n = 436) reported on baseline CD4 count, 13/14 ( n = 543) on baseline viral load and 7/14 ( n = 459) on socio‐demographic characteristics. Among the 14 VF events with genotypic information available at VF , NNRTI RAMs were identified in 13/14 individuals, INI RAMs in 9/14 and dual‐class resistance in 8/14 individuals. Post‐ VF regimens were reported for 16/36 individuals with VF and included lenacapavir ( LEN )‐based regimens, protease inhibitor ( PI )‐based regimens or LA ‐I CAB + RPV continuation. Re‐suppression outcomes were described in 10 VF events: re‐suppression occurred in 5/10. Conclusions: In OCS , the follow‐up duration was short and VF definitions were highly variable, with few cohorts reporting VF outcomes in people with baseline VL >10 000 c/ mL . VF was frequently accompanied by resistance. Post‐ VF regimens varied, and their success was unclear due to the small sample size.